U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07291323) titled 'Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.' on Dec. 05.
Brief Summary: This first-in-human (FIH) study aims to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JANX011 dosed subcutaneously (and potentially intravenously) in healthy adult volunteers (HVs) to gain insight into its therapeutic utility in patients with autoimmune diseases.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Autoimmune
Intervention:
DRUG: JANX011
JANX011 is administered subcutaneously, one time.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Janux Thera...